Intrexon | XON - Operating Profit


Intrexon reported $-60.84M in Operating Profit for its fiscal quarter ending in June of 2024.





Operating Profit Change Date
Agenus USD 14.4M 19.26M Dec/2025
Alaunos Therapeutics USD -1.19M 148K Sep/2025
Amgen USD 3.83B 130M Mar/2026
Anika Therapeutics USD 646K 3.88M Dec/2025
Arrowhead Research USD 40.81M 3.3M Dec/2025
AstraZeneca USD 7.11B 4.14B Mar/2026
Bristol-Myers Squibb USD 4.2B 562M Dec/2025
Gilead Sciences USD 2.96B 551M Dec/2025
GlaxoSmithKline GBP 2.29B 856M Mar/2026
Heron Therapeutics USD 38K 3.83M Dec/2025
Incyte USD 324.17M 59.7M Mar/2026
Intrexon USD -60.84M 26.62M Jun/2024
Karyopharm Therapeutics USD -17.84M 13.44M Dec/2025
Ligand Pharmaceuticals USD 158.89M 149.17M Sep/2025
MacroGenics USD -12.1M 30.74M Dec/2025
MannKind USD -69.24M 28.19M Dec/2025
Merck USD -1.88B 8.12B Mar/2026
Novartis USD 4.24B 171M Mar/2026
Rigel Pharmaceuticals USD 14.06M 13.61M Sep/2024
Roche Holding CHF 9.56B 3.8B Dec/2025
Sangamo BioSciences USD -33.51M 12.77M Jun/2024
Thermo Fisher Scientific USD 1.91B 389M Mar/2026
Veracyte USD 24.63M 1.52M Dec/2025
Xencor USD -53.63M 6.11M Dec/2025